Endophthalmitis: sterile unit cefuroxime dose needed

Article

If a sterile unit dose of cefuroxime were available it would become the world standard for endophthalmitis prophylaxis following the startling proof of its efficacy in the ESCRS endophthalmitis study last year. That was the conclusion of a debate for and against intracameral antibiotics at the JCRS Symposium, Controversies in Cataract & Refractive Surgery.

If a sterile unit dose of cefuroxime were available it would become the world standard for endophthalmitis prophylaxis following the startling proof of its efficacy in the ESCRS endophthalmitis study last year. That was the conclusion of a debate for and against intracameral antibiotics at the JCRS Symposium, Controversies in Cataract & Refractive Surgery.

"The risk of TASS from kitchen pharmacy, and the litigious nature of medical practice in the United States, means that cefuroxime is not the prophylaxis of choice there," said Randall Olson, of the John A. Moran centre in the US, speaking against intracameral injection.

Dr Peter Barry, speaking for the protocol, recognised the problems associated with its use. "There are dilution and diluent problems, contamination and dosage risks, and that's why I would urge industry to supply us with a sterile unit dose," he said.

Dr Olson pointed out that pre- and postoperative topical antibiotics provided good coverage, and he would like to see a study testing the efficacy of pre- and postoperative topical application of fourth-generation fluoroquinolones. He added that gram-positive resistance to cefuroxime is increasing.

Dr Barry rejoined that such a study would prove extremely expensive and would encounter ethical dilemmas given a proven, safe treatment already exists. "We're getting an incidence of just 0.05% of endophthalmitis cases with intracameral cefuroxime, showing the best proven prophylaxis for endophthalmitis. It is effective against the majority of the organism.

He added that there are also organisms resistant to fourth-generation fluoroquinolones such as the enterococci and staphylococcus aureus.

Dr Olson concluded that the two were largely in agreement. "If we had a sterile unit dose, intracameral cefuroxime would be the world standard prophylaxis."

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.